Tumor biomarker testing in non-small-cell lung cancer: A decade of change-Reference-Cited by-同舟云学术

Tumor biomarker testing in non-small-cell lung cancer: A decade of change

Published:2018-02 Issue: Volume:116 Page:90-95
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

VanderLaan Paul A.,Rangachari Deepa,Majid Adnan,Parikh Mihir S.,Gangadharan Sidharta P.,Kent Michael S.,McDonald Danielle C.,Huberman Mark S.,Kobayashi Susumu S.,Costa Daniel B.

Funder

American Cancer Society

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer;VanderLaan;Lung Cancer,2014

2. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice;Rangachari;Cancer Treat. Commun.,2015

3. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma;Rangachari;J. Thorac. Oncol.,2017

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-09-11

2. Factors associated with next generation sequencing-based testing among patients with advanced/metastatic non-squamous non-small cell lung cancer: A study using machine learning methods (Preprint);2024-07-16

3. Smoking-Mediated miR-301a/IRF1 Axis Controlling Immunotherapy Response in Lung Squamous Cell Carcinoma Revealed by Bioinformatic Analysis;Cancers;2024-06-13

4. Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to Treatment;Diagnostics;2024-05-11

5. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma;Aging;2024-04-03